Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company’s CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
Looking for a particular Echo Therapeutics employee's phone or email?
The Echo Therapeutics annual revenue was $57000 in 2026.
2 people are employed at Echo Therapeutics.
Echo Therapeutics is based in Iselin, New Jersey.
The NAICS codes for Echo Therapeutics are [3254, 32, 325, 32541, 33, 334].
The SIC codes for Echo Therapeutics are [384, 38].